| Title |
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, August 2012
|
| DOI | 10.1007/s10549-012-2223-1 |
| Pubmed ID | |
| Authors |
Saroj Niraula, Ryan J. O. Dowling, Marguerite Ennis, Martin C. Chang, Susan J. Done, Nicky Hood, Jaime Escallon, Wey Liang Leong, David R. McCready, Michael Reedijk, Vuk Stambolic, Pamela J. Goodwin |
| Abstract |
Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin 500 mg tid after diagnostic core biopsy until definitive surgery. Clinical (weight, symptoms, and quality of life) and blood [fasting serum insulin, glucose, homeostasis model assessment (HOMA), C-reactive protein (CRP), and leptin] attributes were compared pre- and post-metformin as were terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and Ki67 scores (our primary endpoint) in tumor tissue. Thirty-nine patients completed the study. Mean age was 51 years, and metformin was administered for a median of 18 days (range 13-40) up to the evening prior to surgery. 51 % had T1 cancers, 38 % had positive nodes, 85 % had ER and/or PgR positive tumors, and 13 % had HER2 overexpressing or amplified tumors. Mild, self-limiting nausea, diarrhea, anorexia, and abdominal bloating were present in 50, 50, 41, and 32 % of patients, respectively, but no significant decreases were seen on the EORTC30-QLQ function scales. Body mass index (BMI) (-0.5 kg/m(2), p < 0.0001), weight (-1.2 kg, p < 0.0001), and HOMA (-0.21, p = 0.047) decreased significantly while non-significant decreases were seen in insulin (-4.7 pmol/L, p = 0.07), leptin (-1.3 ng/mL, p = 0.15) and CRP (-0.2 mg/L, p = 0.35). Ki67 staining in invasive tumor tissue decreased (from 36.5 to 33.5 %, p = 0.016) and TUNEL staining increased (from 0.56 to 1.05, p = 0.004). Short-term preoperative metformin was well tolerated and resulted in clinical and cellular changes consistent with beneficial anti-cancer effects; evaluation of the clinical relevance of these findings in adequately powered clinical trials using clinical endpoints such as survival is needed. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Belgium | 1 | 25% |
| Italy | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 141 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 137 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 16% |
| Researcher | 20 | 14% |
| Student > Ph. D. Student | 13 | 9% |
| Student > Bachelor | 12 | 9% |
| Student > Postgraduate | 11 | 8% |
| Other | 38 | 27% |
| Unknown | 24 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 40% |
| Biochemistry, Genetics and Molecular Biology | 16 | 11% |
| Agricultural and Biological Sciences | 14 | 10% |
| Nursing and Health Professions | 3 | 2% |
| Sports and Recreations | 3 | 2% |
| Other | 15 | 11% |
| Unknown | 33 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2012.
All research outputs
#13,366,719
of 22,675,759 outputs
Outputs from Breast Cancer Research and Treatment
#2,883
of 4,617 outputs
Outputs of similar age
#93,773
of 169,692 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#31
of 58 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,617 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,692 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.